Also known as: BeOne Medicines
BeOne Medicines is a global oncology company developing and delivering cancer medicines across multiple markets. Founded in 2010 and now based in Basel, it operates as a publicly listed company with broad international R&D and commercialization activity.
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770698 |
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07746141 |
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations |
NOT_YET_RECRUITING | PHASE1 |
| NCT07739459 |
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07733180 |
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07715396 |
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden |
NOT_YET_RECRUITING | PHASE3 |
| NCT07712640 |
A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants |
RECRUITING | PHASE1 |
| NCT07682415 |
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0 |
NOT_YET_RECRUITING | PHASE2 |
| NCT07674810 |
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia |
NOT_YET_RECRUITING | PHASE2 |
| NCT07671339 |
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer |
RECRUITING | PHASE1 |
| NCT07652736 |
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) |
RECRUITING |
